Items where authors include "Rawstron, AC"

Article

Robinson, JI orcid.org/0000-0001-5425-7520, Md Yusof, MY orcid.org/0000-0003-3131-9121, Davies, V et al. (20 more authors) (2022) Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. eBioMedicine, 86. 104343. ISSN 2352-3964

Pepple, S, Arnold, J, Vital, EM orcid.org/0000-0003-1637-4755 et al. (5 more authors) (2022) Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome. ACR Open Rheumatology, 4 (8). pp. 689-699. ISSN 2578-5745

Arnold, J, Vital, EM orcid.org/0000-0003-1637-4755, Dass, S et al. (5 more authors) (2022) A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis. Frontiers in Immunology, 12. 803175. ISSN 1664-3224

Md Yusof, MY orcid.org/0000-0003-3131-9121, Vital, EM orcid.org/0000-0003-1637-4755, McElvenny, DM et al. (7 more authors) (2019) Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology, 71 (11). pp. 1812-1823. ISSN 2326-5191

Holmes, KB, Sadreev, II, Rawstron, AC orcid.org/0000-0003-0798-9790 et al. (4 more authors) (2019) Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. Oncogenesis, 8. 32. ISSN 2157-9024

Rawstron, AC orcid.org/0000-0003-0798-9790, Kreuzer, K-A, Soosapilla, A et al. (30 more authors) (2018) Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B: Clinical Cytometry, 94 (1). pp. 121-128. ISSN 1552-4949

Munir, T, Howard, DR orcid.org/0000-0003-3333-9783, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia, 31 (10). pp. 2085-2093. ISSN 0887-6924

Collett, L, Howard, DR orcid.org/0000-0003-3333-9783, Munir, T et al. (11 more authors) (2017) Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18. 387. ISSN 1745-6215

Oughton, JB orcid.org/0000-0002-2047-804X, Collett, L, Howard, DR orcid.org/0000-0003-3333-9783 et al. (8 more authors) (2017) GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 18. 353. ISSN 1745-6215

Rawstron, AC, Ssemaganda, A, de Tute, R et al. (11 more authors) (2017) Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study. Lancet Haematology, 4 (7). e334-e340. ISSN 2352-3026

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL. Leukemia, 31. pp. 2416-2425. ISSN 0887-6924

Varghese, A, Howard, DR orcid.org/0000-0003-3333-9783, Pocock, C et al. (9 more authors) (2017) Eradication of minimal residual disease improves overall and progression free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: A Phase II trial assessing alemtuzumab consolidation. British Journal of Haematology, 176 (4). pp. 573-582. ISSN 0007-1048

Munshi, NC, Avet-Loiseau, H, Rawstron, AC et al. (8 more authors) (2017) Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncology, 3 (1). pp. 28-35. ISSN 2374-2437

Kwok, M, Rawstron, AC, Varghese, A et al. (6 more authors) (2016) Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood, 128 (24). pp. 2770-2773. ISSN 0006-4971

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, Hockaday, AM et al. (7 more authors) (2016) Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17. 456. ISSN 1745-6215

de Tute, RM, Rawstron, AC, Gregory, WM et al. (9 more authors) (2016) Minimal Residual Disease Following Autologous Stem Cell Transplant In Myeloma: Impact On Outcome Is Independent Of Induction Regimen. Haematologica, 101 (2). e69-e71. ISSN 0390-6078

Md Yusof, MY orcid.org/0000-0003-3131-9121, Vital, EM orcid.org/0000-0003-1637-4755, Das, S et al. (5 more authors) (2015) Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Annals of the Rheumatic Diseases, 74 (9). pp. 1734-1738. ISSN 0003-4967

Vital, EM, Dass, S, Buch, MH orcid.org/0000-0002-8962-5642 et al. (2 more authors) (2015) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Annals of the Rheumatic Diseases, 74 (6). pp. 1195-1201. ISSN 0003-4967

Das, S, Vital, EM, Horton, S et al. (6 more authors) (2014) Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Annals of the Rheumatic Diseases, 73 (5). 909 - 912. ISSN 0003-4967

Monograph

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (9 more authors) (2017) Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Report. National Institute for Health Research , Health Technology Assessment. ISSN 1366-5278

Conference or Workshop Item

Arnold, JE, Vital, EMJ, Dass, S et al. (5 more authors) (2021) P207 A proposal for individually tailored rituximab treatment based on clinical and B-cell biomarkers for remission maintenance in ANCA associated vasculitis. In: British Society for Rheumatology Annual Conference 2021, 26-28 Apr 2021, Online.

Md Yusof, MY orcid.org/0000-0003-3131-9121, Robinson, J, El-Sherbiny, Y et al. (4 more authors) (2019) SAT0009 THE EFFECT OF FCGR3A POLYMORPHISM ON THE INITIAL DEPTH OF B-CELL DEPLETION BY RITUXIMAB, FUNCTIONAL NK-CELL MEDIATED KILLING AND CLINICAL RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS. In: Annual European Congress of Rheumatology, EULAR 2019, 12-15 Jun 2019, Madrid, Spain.

Proceedings Paper

Md Yusof, MY orcid.org/0000-0003-3131-9121, Shaw, D, El-Sherbiny, YM orcid.org/0000-0003-4791-3475 et al. (3 more authors) (2017) Predicting and managing primary and secondary non-response to rituximab using b-cell biomarkers in systemic lupus erythematosus. In: Annals of the Rheumatic Diseases. Annual European Congress of Rheumatology (EULAR 2017), 14-17 Jun 2017, Madrid, Spain. BMJ Publishing Group , p. 869.

Md Yusof, MY orcid.org/0000-0003-3131-9121, Cassamoali, H, Rawstron, AC et al. (4 more authors) (2016) Humanized Anti-CD20 Antibodies Improve Depletion and Response in Systemic Lupus Erythematosus Patients with Resistance to Rituximab: Results from the First 100 Patients at a Single Centre. In: Rheumatology. Rheumatology 2016, 26-28 Apr 2016, Glasgow, UK. Oxford University Press , i46-i47.